These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28284804)

  • 1. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
    Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
    Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
    Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
    Grewal AS; Sekhon BS; Lather V
    Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
    Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a new class of glucokinase activators through structure-based design.
    Hinklin RJ; Boyd SA; Chicarelli MJ; Condroski KR; DeWolf WE; Lee PA; Lee W; Singh A; Thomas L; Voegtli WC; Williams L; Aicher TD
    J Med Chem; 2013 Oct; 56(19):7669-78. PubMed ID: 24015910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM; Bhuniya D; De S; Dave B; Vyavahare VP; Kurhade SH; Kandalkar SR; Naik KP; Kobal BS; Kaduskar RD; Basu S; Jain V; Patil P; Chaturvedi Joshi S; Bhat G; Raje AA; Reddy S; Gundu J; Madgula V; Tambe S; Shitole P; Umrani D; Chugh A; Palle VP; Mookhtiar KA
    Eur J Med Chem; 2017 Jun; 133():268-286. PubMed ID: 28390958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R; Berthel SJ; Kester RF; Tilley JW
    Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M
    Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
    Park K
    Arch Pharm Res; 2012 Dec; 35(12):2029-33. PubMed ID: 23263798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
    De Ceuninck F; Kargar C; Ilic C; Caliez A; Rolin JO; Umbdenstock T; Vinson C; Combettes M; de Fanti B; Harley E; Sadlo M; Lefèvre AL; Broux O; Wierzbicki M; Fourquez JM; Perron-Sierra F; Kotschy A; Ktorza A
    Br J Pharmacol; 2013 Jan; 168(2):339-53. PubMed ID: 22925001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
    Wang Z; Shi X; Zhang H; Yu L; Cheng Y; Zhang H; Zhang H; Zhou J; Chen J; Shen X; Duan W
    Eur J Med Chem; 2017 Oct; 139():128-152. PubMed ID: 28800453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
    Guertin KR; Grimsby J
    Curr Med Chem; 2006; 13(15):1839-43. PubMed ID: 16787225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
    De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
    Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator.
    Hinklin RJ; Baer BR; Boyd SA; Chicarelli MD; Condroski KR; DeWolf WE; Fischer J; Frank M; Hingorani GP; Lee PA; Neitzel NA; Pratt SA; Singh A; Sullivan FX; Turner T; Voegtli WC; Wallace EM; Williams L; Aicher TD
    Bioorg Med Chem; 2020 Jan; 28(1):115232. PubMed ID: 31818630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
    Stevens BD; Litchfield J; Pfefferkorn JA; Atkinson K; Perreault C; Amor P; Bahnck K; Berliner MA; Calloway J; Carlo A; Derksen DR; Filipski KJ; Gumkowski M; Jassal C; MacDougall M; Murphy B; Nkansah P; Pettersen J; Rotter C; Zhang Y
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6588-92. PubMed ID: 24239482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.